Bristol-Myers Squibb Company (BMY) fair value analysis

S&P 500 · Updated 2026-09-07

Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines for treating diseases including cancer, cardiovascular disease, immunology conditions, and cell therapy. The company operates research, development, and manufacturing facilities across multiple countries worldwide and sells its products to healthcare systems and patients internationally.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, BMY is trading at more than a 25% premium to estimated fair value.

BMY currently ranks #100 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $66.82
Sector: Healthcare
12-month range: $46.02–$66.92

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: C
Leverage: High
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for BMY

Our model validated 17 trailing price-to-earnings windows for BMY, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $46.02–$66.92.
The 14-day relative strength index sits at a neutral 57.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for BMY
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent BMY news

TickrTrends' derived news-sentiment signal for BMY is currently leaning positive, computed from recent coverage.

Bristol Myers Squibb: Still Cheap, Despite What The Chart Says (NYSE:BMY) (seekingalpha.com, 2026-09-04)
TickrTrends take: Bristol Myers Squibb trades in the Healthcare sector where valuation metrics carry particular weight given the capital-intensive nature of drug development and approval timelines. Despite the current TickrTrends verdict of Overvalued, the headline suggests some analysts view underlying fundamentals as supportive relative to price, indicating a potential disconnect between technical chart patterns and intrinsic value assessments. Investors focused on valuation should monitor whether BMY's pipeline progress, patent expirations, and earnings trajectory align with current market pricing over coming quarters.
Bristol Myers Squibb: Buy The Growth Portfolio At A Value Price (NYSE:BMY) (seekingalpha.com, 2026-09-04)
TickrTrends take: Bristol Myers Squibb trades at a valuation that TickrTrends currently classifies as overvalued, which contrasts with market commentary suggesting value opportunities in the company's growth portfolio. For investors focused on valuation metrics, the gap between current market pricing and TickrTrends' assessment represents a key tension point to monitor as the Healthcare sector company's financial results develop. This discrepancy underscores the importance of tracking whether BMY's growth trajectory justifies its present valuation or whether the overvalued designation reflects near-term compression risk.
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? (finance.yahoo.com, 2026-09-03)
TickrTrends take: Bristol-Myers Squibb currently trades at a valuation that TickrTrends identifies as overvalued within the Healthcare sector, which creates a particular context for evaluating whether recent performance metrics represent genuine outperformance or reflect valuation expansion. A reader focused on valuation should monitor whether BMY's operational performance justifies its current premium relative to healthcare peers, as outperformance at an already elevated valuation may signal limited margin of safety. The gap between sector performance and BMY's stock price movement becomes especially relevant when assessing entry points and risk-reward positioning.

What people are saying

Follow the BMY conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — # BMY Weekly Indicator Summary TickrTrends' derived indicators for BMY showed a notable shift this week, with the momentum indicator declining from a B rating to none. Given the current valuation verdict of Overvalued, this loss of momentum represents a weakening technical position for the Healthcare sector stock. The combination of deteriorating momentum and stretched valuation metrics suggests reduced upside catalysts in the near term.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is BMY stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), BMY is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is BMY's TickrTrends verdict?

BMY's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does BMY compare to other Healthcare stocks?

BMY ranks #100 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is BMY overbought or oversold?

BMY's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

BMY vs AMGN · BMY vs CAH · BMY vs CNC · BMY vs CRL · BMY vs DGX